BRAFV600E通过旁路机制主导甲状腺癌中的NOTCH信号通路
研究利用BRAFV600E驱动的甲状腺乳头状癌小鼠模型及细胞系,探讨NOTCH通路与MAP激酶通路的交互作用。结果发现BRAFV600E突变合并NOTCH胞内域过表达导致肿瘤更大、侵袭性更强且总生存期缩短,而RBP-jκ缺失未改变表型;BRAFV600E突变细胞对NOTCH抑制耐药,MEK1/2抑制对Hes1/Hey1转录的影响更显著。提示MAP激酶活性在甲状腺癌中可覆盖NOTCH通路效应。
要点
- BRAFV600E突变合并NOTCH胞内域过表达促进甲状腺肿瘤生长并降低生存。
- BRAFV600E突变甲状腺癌细胞对NOTCH通路药理抑制具有抵抗性。
- MEK1/2抑制对Hes1/Hey1转录的影响强于NOTCH抑制。
核心结论
- BRAFV600E突变可能绕过NOTCH通路并对NOTCH下游靶点发挥强正向效应。
- MAP激酶活性在甲状腺癌背景下覆盖NOTCH通路的作用。
研究设计与样本
- 研究采用BRAFV600E驱动的甲状腺乳头状癌小鼠模型,并施加NOTCH通路遗传学改变,通过超声随访肿瘤负荷。
- 进一步分析使用转染NOTCHIC或BRAFV600E的甲状腺乳头状癌细胞系或非癌细胞,并给予MAP激酶或NOTCH通路抑制剂处理。
主要发现
- BRAFV600E突变合并NOTCH胞内域过表达导致小鼠甲状腺肿瘤显著更大、癌更具侵袭性且总生存期缩短。
- 上述肿瘤虽更呈囊性,但未进展为未分化甲状腺癌。
- RBP-jκ缺失未改变小鼠表型。
- BRAFV600E突变的甲状腺乳头状癌细胞系对NOTCH通路药理抑制 resistant。
- 在BRAFV600E突变细胞系中,抑制MEK1/2对Hes1/Hey1转录的影响比NOTCH抑制更显著。
临床怎么用
- 对于BRAFV600E突变甲状腺癌,单纯靶向NOTCH通路可能疗效有限,需考虑MAP激酶通路的主导作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Several mechanisms likely cooperate with the mitogen-activated protein (MAP)-kinase pathway to promote cancer progression in the thyroid. One putative pathway is NOTCH signaling, which is implicated in several other malignancies. In thyroid cancer, data regarding the role of the NOTCH pathway are insufficient and even contradictory. Methods: A BRAFV600E-driven papillary thyroid carcinoma (PTC) mouse model was subjected to NOTCH pathway genetic alterations, and the tumor burden was followed by ultrasound. Further analyses were performed on PTC cell lines or noncancerous cells transfected with NOTCHIC or BRAFV600E, which were then subjected to pharmacological treatment with MAP-kinase or NOTCH pathway inhibitors. Results: The presence of the BRAFV600E mutation coupled with overexpression of the NOTCH intracellular domain led to significantly bigger thyroid tumors in mice, to a more aggressive carcinoma, and decreased overall survival. Although more cystic, the tumors did not progress into anaplastic thyroid carcinomas. On the contrary, the deletion of RBP-jκ (a major cofactor involved in NOTCH signaling) did not alter the phenotype in mice. BRAFV600E-mutated PTC cell lines were resistant to pharmacological inhibition of the NOTCH pathway. Inhibition of MEK1/2 uncovered a predominant effect on Hes1/Hey1 transcription compared with NOTCH inhibition in BRAFV600E-mutated cell lines. Finally, γ-secretase activity and γ-secretase subunit transcription levels were dependent on ERK activation. Our findings suggest that MAP-kinase activity overrides the NOTCH pathway in the context of thyroid cancer. Conclusions: The interaction between the BRAF and NOTCH pathways demonstrates that the BRAFV600E mutation might bypass NOTCH and exert a strong positive effect on NOTCH downstream targets in thyroid carcinoma.
引用
- Traversi F, Stooss A, Dettmer MS, et al. BRAFV600E Overrides NOTCH Signaling in Thyroid Cancer. Thyroid. 2020. PMID: 33012268. doi:10.1089/thy.2019.0595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。